Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases.

IF 5.1 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM Journal of Bone and Mineral Research Pub Date : 2024-08-05 DOI:10.1093/jbmr/zjae059
Eng Hooi Tan, Trishna Rathod-Mistry, Victoria Y Strauss, James O'Kelly, Francesco Giorgianni, Richard Baxter, Vanessa C Brunetti, Alma Becic Pedersen, Vera Ehrenstein, Daniel Prieto-Alhambra
{"title":"Evaluating the comparability of osteoporosis treatments using propensity score and negative control outcome methods in UK and Denmark electronic health record databases.","authors":"Eng Hooi Tan, Trishna Rathod-Mistry, Victoria Y Strauss, James O'Kelly, Francesco Giorgianni, Richard Baxter, Vanessa C Brunetti, Alma Becic Pedersen, Vera Ehrenstein, Daniel Prieto-Alhambra","doi":"10.1093/jbmr/zjae059","DOIUrl":null,"url":null,"abstract":"<p><p>Evidence on the comparative effectiveness of osteoporosis treatments is heterogeneous. This may be attributed to different populations and clinical practice, but also to differing methodologies ensuring comparability of treatment groups before treatment effect estimation and the amount of residual confounding by indication. This study assessed the comparability of denosumab vs oral bisphosphonate (OBP) groups using propensity score (PS) methods and negative control outcome (NCO) analysis. A total of 280 288 women aged ≥50 yr initiating denosumab or OBP in 2011-2018 were included from the UK Clinical Practice Research Datalink (CPRD) and the Danish National Registries (DNR). Balance of observed covariates was assessed using absolute standardized mean difference (ASMD) before and after PS weighting, matching, and stratification, with ASMD >0.1 indicating imbalance. Residual confounding was assessed using NCOs with ≥100 events. Hazard ratio (HR) and 95%CI between treatment and NCO were estimated using Cox models. Presence of residual confounding was evaluated with 2 approaches (1) >5% of NCOs with 95% CI excluding 1, (2) >5% of NCOs with an upper CI <0.75 or lower CI >1.3. The number of imbalanced covariates before adjustment (CPRD 22/87; DNR 18/83) decreased, with 2%-11% imbalance remaining after weighting, matching, or stratification. Using approach 1, residual confounding was present for all PS methods in both databases (≥8% of NCOs), except for stratification in DNR (3.8%). Using approach 2, residual confounding was present in CPRD with PS matching (5.3%) and stratification (6.4%), but not with weighting (4.3%). Within DNR, no NCOs had HR estimates with upper or lower CI limits beyond the specified bounds indicating residual confounding for any PS method. Achievement of covariate balance and determination of residual bias were dependent upon several factors including the population under study, PS method, prevalence of NCO, and the threshold indicating residual confounding.</p>","PeriodicalId":185,"journal":{"name":"Journal of Bone and Mineral Research","volume":null,"pages":null},"PeriodicalIF":5.1000,"publicationDate":"2024-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bone and Mineral Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jbmr/zjae059","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Evidence on the comparative effectiveness of osteoporosis treatments is heterogeneous. This may be attributed to different populations and clinical practice, but also to differing methodologies ensuring comparability of treatment groups before treatment effect estimation and the amount of residual confounding by indication. This study assessed the comparability of denosumab vs oral bisphosphonate (OBP) groups using propensity score (PS) methods and negative control outcome (NCO) analysis. A total of 280 288 women aged ≥50 yr initiating denosumab or OBP in 2011-2018 were included from the UK Clinical Practice Research Datalink (CPRD) and the Danish National Registries (DNR). Balance of observed covariates was assessed using absolute standardized mean difference (ASMD) before and after PS weighting, matching, and stratification, with ASMD >0.1 indicating imbalance. Residual confounding was assessed using NCOs with ≥100 events. Hazard ratio (HR) and 95%CI between treatment and NCO were estimated using Cox models. Presence of residual confounding was evaluated with 2 approaches (1) >5% of NCOs with 95% CI excluding 1, (2) >5% of NCOs with an upper CI <0.75 or lower CI >1.3. The number of imbalanced covariates before adjustment (CPRD 22/87; DNR 18/83) decreased, with 2%-11% imbalance remaining after weighting, matching, or stratification. Using approach 1, residual confounding was present for all PS methods in both databases (≥8% of NCOs), except for stratification in DNR (3.8%). Using approach 2, residual confounding was present in CPRD with PS matching (5.3%) and stratification (6.4%), but not with weighting (4.3%). Within DNR, no NCOs had HR estimates with upper or lower CI limits beyond the specified bounds indicating residual confounding for any PS method. Achievement of covariate balance and determination of residual bias were dependent upon several factors including the population under study, PS method, prevalence of NCO, and the threshold indicating residual confounding.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
在英国和丹麦的电子健康记录数据库中使用倾向得分和阴性对照结果方法评估骨质疏松症治疗的可比性。
有关骨质疏松症治疗效果比较的证据不尽相同。这可能归因于不同的人群和临床实践,同时也与不同的方法有关,这些方法确保了治疗效果评估前治疗组的可比性,以及适应症的残余混淆量。本研究采用倾向评分(PS)方法和阴性对照结果(NCO)分析评估了地诺单抗与口服双膦酸盐(OBP)组的可比性。英国临床实践研究数据链(CPRD)和丹麦国家登记处(DNR)共纳入了280 288名年龄≥50岁、在2011年至2018年期间开始使用地诺单抗或OBP的女性。使用PS加权、匹配和分层前后的绝对标准化均值差(ASMD)评估观察协变量的平衡性,ASMD>0.1表示不平衡。使用事件数≥100 的 NCO 评估残余混杂因素。使用 Cox 模型估算治疗与 NCO 之间的危险比 (HR) 和 95% 置信区间 (CI)。评估残余混杂的方法有两种1:>5% 的 NCO,95% CI 不包括1,2 >5% 的 NCO,CI 上限为 1.3。调整前不平衡协变量的数量减少(CPRD 22/87;DNR 18/83),加权、匹配或分层后仍有 2-11% 的不平衡。使用方法 1,两个数据库中所有 PS 方法都存在残余混杂(≥8% 的 NCOs),但 DNR 的分层方法除外(3.8%)。在 CPRD 中,采用方法 2,PS 匹配(5.3%)和分层(6.4%)均存在残余混杂,但加权(4.3%)则不存在残余混杂。在 DNR 中,没有任何 NCO 的 HR 估计值的 CI 上限或下限超出规定范围,这表明任何 PS 方法都存在残余混杂。协变量平衡的实现和残余偏倚的确定取决于多个因素,包括研究人群、PS 方法、NCO 发生率和表明残余混杂的阈值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Bone and Mineral Research
Journal of Bone and Mineral Research 医学-内分泌学与代谢
CiteScore
11.30
自引率
6.50%
发文量
257
审稿时长
2 months
期刊介绍: The Journal of Bone and Mineral Research (JBMR) publishes highly impactful original manuscripts, reviews, and special articles on basic, translational and clinical investigations relevant to the musculoskeletal system and mineral metabolism. Specifically, the journal is interested in original research on the biology and physiology of skeletal tissues, interdisciplinary research spanning the musculoskeletal and other systems, including but not limited to immunology, hematology, energy metabolism, cancer biology, and neurology, and systems biology topics using large scale “-omics” approaches. The journal welcomes clinical research on the pathophysiology, treatment and prevention of osteoporosis and fractures, as well as sarcopenia, disorders of bone and mineral metabolism, and rare or genetically determined bone diseases.
期刊最新文献
The Quantification of Bone Mineral Density Using Photon Counting Computed Tomography and its Implications for Detecting Bone Remodelling. 24-Hour Activity Composition is Associated with Lower Fall and Fracture Risk in Older Men. A quasi-experimental study about shared decision-making and motivational interviewing on patients with a recent fracture attending a fracture liaison services. Atypical fractures at non-classical sites associated with anti-resorptive therapy: A Systematic Review. Epidural Steroid Injections and Fracture Incidence Among Older Individuals with Radiculopathy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1